Zenas BioPharma is a clinical-stage biopharmaceutical company focused on therapies for autoimmune and inflammatory diseases. Its programs aim at immune-mediated conditions where existing treatments leave significant unmet need. With little to no product revenue yet, the business centers on research, clinical development and advancing candidates through late-stage trials.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -52.2 | — |
| Q3 2025 | 0 | — | -51.5 | — |
| Q4 2025 | 0 | — | -240.4 | — |
| Q1 2026 | 0 | — | -81 | — |
| Q2 2026 | 1 | — | -111.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: QCR Holdings, Inc. (QCRH), NextNav Inc. (NN), Hub Group, Inc. (HUBG), Omnicell, Inc. (OMCL), Alphatec Holdings, Inc. (ATEC), ICF International, Inc. (ICFI)